CN114375290B - 制备化合物的新颖合成选项 - Google Patents

制备化合物的新颖合成选项 Download PDF

Info

Publication number
CN114375290B
CN114375290B CN202080041935.8A CN202080041935A CN114375290B CN 114375290 B CN114375290 B CN 114375290B CN 202080041935 A CN202080041935 A CN 202080041935A CN 114375290 B CN114375290 B CN 114375290B
Authority
CN
China
Prior art keywords
compound
acid
formula
alkyl
hours
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN202080041935.8A
Other languages
English (en)
Chinese (zh)
Other versions
CN114375290A (zh
Inventor
N·库尼埃
范瑜
S·科洛图钦
S·慕克吉
E·M·西蒙斯
A·辛格
魏依柔
肖毅
袁昌夏
郑斌
S·A·瓦格沙尔
D·F·D·布罗吉尼
D·C·T·曹
K·切尔尼琴科
S·F·E·勒梅尔
C·本·海姆
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Janssen Pharmaceutica NV
Bristol Myers Squibb Co
Original Assignee
Janssen Pharmaceutica NV
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica NV, Bristol Myers Squibb Co filed Critical Janssen Pharmaceutica NV
Priority to CN202411615118.5A priority Critical patent/CN119775276A/zh
Publication of CN114375290A publication Critical patent/CN114375290A/zh
Application granted granted Critical
Publication of CN114375290B publication Critical patent/CN114375290B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/18—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/61—Halogen atoms or nitro radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
CN202080041935.8A 2019-04-11 2020-04-10 制备化合物的新颖合成选项 Active CN114375290B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202411615118.5A CN119775276A (zh) 2019-04-11 2020-04-10 制备化合物的新颖合成选项

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962832614P 2019-04-11 2019-04-11
US62/832,614 2019-04-11
PCT/US2020/027655 WO2020210613A1 (en) 2019-04-11 2020-04-10 Novel synthetic options towards the manufacture of (6r,10s)-10- {4-[5-chloro-2-(4-chloro-1h-1,2,3-triazol-1-yl)phenyl]-6-oxo-1(6h)- pyrimidinyl}- 1-(difluoromethyl)-6-methyl-1,4,7,8,9,10-hexahydro-11,15 -(metheno)pyrazolo [4,3-b] [1,7] diazacyclotetradecin-5(6h)-one

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202411615118.5A Division CN119775276A (zh) 2019-04-11 2020-04-10 制备化合物的新颖合成选项

Publications (2)

Publication Number Publication Date
CN114375290A CN114375290A (zh) 2022-04-19
CN114375290B true CN114375290B (zh) 2024-11-29

Family

ID=70457148

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202080041935.8A Active CN114375290B (zh) 2019-04-11 2020-04-10 制备化合物的新颖合成选项
CN202411615118.5A Pending CN119775276A (zh) 2019-04-11 2020-04-10 制备化合物的新颖合成选项

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202411615118.5A Pending CN119775276A (zh) 2019-04-11 2020-04-10 制备化合物的新颖合成选项

Country Status (16)

Country Link
US (2) US12378246B2 (https=)
EP (2) EP4234555A3 (https=)
JP (2) JP7631218B2 (https=)
KR (2) KR20260047658A (https=)
CN (2) CN114375290B (https=)
AR (1) AR118649A1 (https=)
AU (2) AU2020272973B2 (https=)
BR (1) BR112021020368A2 (https=)
CA (1) CA3132365A1 (https=)
EA (1) EA202192807A1 (https=)
ES (1) ES2969253T3 (https=)
IL (1) IL287102B2 (https=)
MX (2) MX2021012286A (https=)
SG (1) SG11202111132WA (https=)
TW (1) TWI880924B (https=)
WO (1) WO2020210613A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4133064A4 (en) 2020-04-10 2024-07-24 Codexis, Inc. Engineered transaminase polypeptides
TW202229280A (zh) * 2020-10-12 2022-08-01 美商必治妥美雅史谷比公司 （６ｒ，１０ｓ）－１０－｛４－［５－氯－２－（４－氯－１ｈ－１，２，３－三唑－１－基）苯基］－６－側氧基－１（６ｈ）－嘧啶基｝－１－（二氟甲基）－６－甲基－１，４，７，８，９，１０－六氫－１１，１５－（亞甲橋基）吡唑并［４，３－ｂ］［１，７］二氮雜環十四炔－５（６ｈ）－酮之製備方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105294496A (zh) * 2015-09-28 2016-02-03 中山大学 一种西酞普兰中间体的制备方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012125797A1 (en) 2011-03-15 2012-09-20 Abbott Laboratories Nuclear hormone receptor modulators
SG10201908467RA (en) 2014-01-31 2019-10-30 Bristol Myers Squibb Co Macrocycles with hetrocyclic p2' groups as factor xia inhibitors
NO2721243T3 (https=) 2014-10-01 2018-10-20
US9453018B2 (en) 2014-10-01 2016-09-27 Bristol-Myers Squibb Company Pyrimidinones as factor XIa inhibitors
CN110062757B (zh) 2017-01-18 2022-03-04 广东东阳光药业有限公司 凝血因子XIa抑制剂及其用途
WO2020211781A1 (zh) * 2019-04-16 2020-10-22 南京明德新药研发有限公司 作为XIa因子抑制剂的大环衍生物
CN114008047B (zh) * 2019-07-23 2023-03-21 南京明德新药研发有限公司 作为XIa因子抑制剂的大环衍生物
JP7747337B2 (ja) * 2020-04-10 2025-10-01 コデクシス， インコーポレイテッド 速度論的光学分割のためのカルボキシエステラーゼポリペプチド

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105294496A (zh) * 2015-09-28 2016-02-03 中山大学 一种西酞普兰中间体的制备方法

Also Published As

Publication number Publication date
EP3953334A1 (en) 2022-02-16
TWI880924B (zh) 2025-04-21
US20220144836A1 (en) 2022-05-12
IL287102A (en) 2021-12-01
AR118649A1 (es) 2021-10-20
KR20220045105A (ko) 2022-04-12
BR112021020368A2 (pt) 2021-12-07
EP4234555A2 (en) 2023-08-30
JP2022526659A (ja) 2022-05-25
TW202104188A (zh) 2021-02-01
ES2969253T3 (es) 2024-05-17
IL287102B1 (en) 2025-08-01
EP3953334B1 (en) 2023-11-22
CN119775276A (zh) 2025-04-08
CA3132365A1 (en) 2020-10-15
WO2020210613A1 (en) 2020-10-15
AU2020272973B2 (en) 2025-11-27
IL287102B2 (en) 2025-12-01
EP4234555A3 (en) 2024-01-03
KR102929951B1 (ko) 2026-02-24
SG11202111132WA (en) 2021-11-29
JP7631218B2 (ja) 2025-02-18
EA202192807A1 (ru) 2022-02-24
MX2021012286A (es) 2022-04-06
MX2025014306A (es) 2026-01-07
JP2025084766A (ja) 2025-06-03
AU2020272973A1 (en) 2021-12-02
CN114375290A (zh) 2022-04-19
KR20260047658A (ko) 2026-04-08
US12378246B2 (en) 2025-08-05
AU2026201396A1 (en) 2026-03-19
US20260092066A1 (en) 2026-04-02

Similar Documents

Publication Publication Date Title
EP2968299B1 (en) Compounds and uses thereof for the modulation of hemoglobin
JP2025084766A (ja) （６ｒ，１０ｓ）－１０－｛４－［５－クロロ－２－（４－クロロ－１ｈ－１，２，３－トリアゾール－１－イル）フェニル］－６－オキソ－１（６ｈ）－ピリミジニル｝－１－（ジフルオロメチル）－６－メチル－１，４，７，８，９，１０－ヘキサヒドロ－１１，１５－（メタノ）ピラゾロ［４，３－ｂ］［１，７］ジアザシクロテトラデシン－５（６ｈ）－オンの製造における新規合成法
JP2013170151A (ja) インドール‐３−トリフロン類の直接的製造法及びインドールトリフロン誘導体
CA2837529C (en) Positive allosteric modulators of nicotinic acetylcholine receptor
IL323810A (en) Synthesis of ras inhibitors
Corey et al. Improved enantioselective dihydroxylation of bishomoallylic alcohol derivatives using a mechanistically inspired bis-Cinchona alkaloid catalyst
KR20010005567A (ko) 퀴놀린-2-카르복실산 유도체 및 그의 흥분성 아미노산 길항제로서의 용도
CN103373948B (zh) 一种天然产物(-)-海人草酸的制备方法
HK40124045A (zh) 制备化合物的新颖合成选项
CN116444419A (zh) 一种靛红环外双烯结构化合物及制备方法
CN103288871A (zh) 一种制备二羟基酸HMG-CoA还原酶抑制剂用的中间体及其制备方法和应用
Cui et al. Lewis acid catalyzed diastereoselective vinylogous Mannich reaction induced by O-pivaloylated d-galactosylamine as the chiral auxiliary: stereoselective synthesis of 6-arylpiperidin-2-ones
JP4524845B2 (ja) アミノ基を有する光学活性アリルアルコール誘導体の製造方法、および光学活性化合物
Hiroya et al. Functionalization of N-tosyl-2-pyridinone with silyl ketene acetal catalyzed by Lewis acid, and synthetic studies of corynantheidol
CN121270465A (zh) 一种手性磷酸与路易斯酸协同催化下合成α-位手性中心的氮杂芳环的方法
CN117377660A (zh) 用于苯并氧氮杂䓬恶唑烷酮化合物的制备的方法
NZ710003B2 (en) Positive allosteric modulators of nicotinic acetylcholine receptor
NZ617367B2 (en) Positive allosteric modulators of nicotinic acetylcholine receptor
JP2000026455A (ja) ３−アミノチオフェン誘導体
NZ717556A (en) Spirocyclic compounds as tryptophan hydroxylase inhibitors
HK1181384A1 (en) Method for producing substituted pyridin-2-one
HK1181384B (en) Method for producing substituted pyridin-2-one

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant